CD40 ligand upregulates expression of the IL-3 receptor and stimulates proliferation of B-lineage acute lymphoblastic leukemia cells in the presence of IL-3

Leukemia. 2000 Mar;14(3):403-11. doi: 10.1038/sj.leu.2401682.

Abstract

The proliferative response of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells to IL-3 is dependent on the expression of functional IL-3 receptors (IL-3R). Here we report that CD40 ligand (CD40L) in the presence of recombinant IL-3 increased proliferation of BCP-ALL cells by upregulating expression of IL-3R. Upregulation of IL-3R in BCP-ALL cells was observed as early as 1 h after treatment with CD40L, and a 50- to 500-fold increase of IL-3R expression after 24 h was detected in all 12 cases studied. Moreover, expression of receptors for IL-7 (IL-7R) and stem cell factor (SCF-R, c-Kit) was also induced by CD40L in the majority of BCP-ALL cases examined; however, levels of induction were low compared to those for IL-3R. To test the functional activity of upregulated receptors for IL-3, SCF and IL-7, we evaluated the proliferation and growth of BCP-ALL cells cultured in serum-free media with CD40L plus these factors. When CD40L was added with either a single cytokine (IL-3, SCF and IL-7) or their combinations, cell proliferation was significantly increased as detected by DNA synthesis assay. Combinations of CD40L plus IL-3 and either SCF or IL-7 were able to support long-term growth of BCP-ALL cells for at least 8 weeks in three of the seven cases studied. Immunophenotyping and gene rearrangement studies indicated that cells in long-term cultures were monoclonal and retained their original phenotypes. The leukemic cells remained primarily dependent on the presence of IL-3 and its receptor for long-term growth, as shown by selective withdrawal of growth factors or antibody blockade of receptors. These results suggest an important role for CD40L in upregulating expression of IL-3R on BCP-ALL cells and enabling these cells to proliferate in long-term cultures in the presence of IL-3 and either SCF or IL-7.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Burkitt Lymphoma / pathology*
  • CD40 Ligand
  • Cell Division / drug effects
  • Child
  • Child, Preschool
  • Culture Media, Serum-Free / pharmacology
  • DNA, Neoplasm / genetics
  • Female
  • Gene Expression Regulation, Leukemic / drug effects*
  • Gene Rearrangement, B-Lymphocyte
  • Genes, Immunoglobulin
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Immunophenotyping
  • Infant
  • Interleukin-3 / pharmacology*
  • Interleukin-7 / pharmacology
  • Male
  • Membrane Glycoproteins / pharmacology*
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Polymerase Chain Reaction
  • Proto-Oncogene Proteins c-kit / biosynthesis
  • Proto-Oncogene Proteins c-kit / genetics
  • Receptors, Interleukin-3 / biosynthesis*
  • Receptors, Interleukin-3 / genetics
  • Receptors, Interleukin-7 / biosynthesis
  • Receptors, Interleukin-7 / genetics
  • Stem Cell Factor / pharmacology
  • Tumor Cells, Cultured / drug effects
  • Up-Regulation / drug effects*

Substances

  • Culture Media, Serum-Free
  • DNA, Neoplasm
  • Immunoglobulin Heavy Chains
  • Interleukin-3
  • Interleukin-7
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • Receptors, Interleukin-3
  • Receptors, Interleukin-7
  • Stem Cell Factor
  • CD40 Ligand
  • Proto-Oncogene Proteins c-kit